Citius Pharmaceuticals, Inc.
CTXR
$1.29
$0.032.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.71M | 31.41M | 31.28M | 30.09M | 29.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.14M | 42.99M | 42.69M | 42.00M | 41.07M |
| Operating Income | -41.14M | -42.99M | -42.69M | -42.00M | -41.07M |
| Income Before Tax | -41.14M | -42.63M | -39.78M | -38.85M | -37.72M |
| Income Tax Expenses | 936.60K | 816.40K | 696.20K | 576.00K | 576.00K |
| Earnings from Continuing Operations | -42.07 | -43.44 | -40.48 | -39.43 | -38.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.81M | 1.40M | 800.00K | 287.00K | -- |
| Net Income | -40.26M | -42.05M | -39.68M | -39.14M | -38.29M |
| EBIT | -41.14M | -42.99M | -42.69M | -42.00M | -41.07M |
| EBITDA | -41.14M | -42.98M | -42.69M | -41.99M | -41.07M |
| EPS Basic | -4.97 | -5.73 | -5.80 | -5.95 | -6.11 |
| Normalized Basic EPS | -2.89 | -3.36 | -3.67 | -3.80 | -3.85 |
| EPS Diluted | -5.08 | -5.84 | -5.92 | -6.06 | -6.15 |
| Normalized Diluted EPS | -2.89 | -3.36 | -3.67 | -3.80 | -3.85 |
| Average Basic Shares Outstanding | 34.31M | 30.26M | 28.04M | 26.91M | 26.03M |
| Average Diluted Shares Outstanding | 34.31M | 30.26M | 28.04M | 26.91M | 26.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |